These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26678201)

  • 1. Maintenance treatment in metastatic colorectal cancer.
    Simkens LH; van Tinteren H; Punt CJ; Koopman M
    Lancet Oncol; 2015 Dec; 16(16):e582-3. PubMed ID: 26678201
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintenance treatment in metastatic colorectal cancer.
    Chibaudel B; Bonnetain F; Tournigand C; de Gramont A
    Lancet Oncol; 2015 Dec; 16(16):e583-4. PubMed ID: 26678202
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintenance therapy for metastatic colorectal cancer.
    Giampieri R; Cascinu S
    Lancet Oncol; 2015 Oct; 16(13):1281-2. PubMed ID: 26361970
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance treatment in metastatic colorectal cancer - Authors' reply.
    Hegewisch-Becker S; Graeven U; Arnold D
    Lancet Oncol; 2015 Dec; 16(16):e584-5. PubMed ID: 26678203
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
    Rahman A
    Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
    Kim S; Cayre A; Jary M; Jacquin M; Arbez-Gindre F; Fein F; Lakkis Z; Nguyen T; Borg C
    Clin Colorectal Cancer; 2016 Dec; 15(4):e229-e234. PubMed ID: 27600470
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
    Semira C; Wong HL; Field K; Lee M; Lee B; Nott L; Shapiro J; Wong R; Tie J; Tran B; Richardson G; Zimet A; Lipton L; Tamjid B; Burge M; Ma B; Johns J; Harold M; Gibbs P
    Intern Med J; 2019 Apr; 49(4):446-454. PubMed ID: 30230679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
    Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
    Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
    Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
    Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
    [No Abstract]   [Full Text] [Related]  

  • 12. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
    Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
    World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
    Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
    Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
    Miyamoto Y; Oki E; Emi Y; Tokunaga S; Shimokawa M; Ogata Y; Akagi Y; Sakamoto Y; Tanaka T; Saeki H; Maehara Y; Baba H
    Anticancer Res; 2018 Jan; 38(1):491-499. PubMed ID: 29277814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
    Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
    BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
    Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
    Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
    Chen J; Smalligan RD; Nadesan S
    Hosp Pract (1995); 2016 Aug; 44(3):120-2. PubMed ID: 27309405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
    Díaz-Rubio E; Pietrantonio F; de Braud F
    Oncologist; 2012; 17(11):1426-8. PubMed ID: 23073991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.